Best of ASCO 2026 UAE conference launches in Al Ain
Abu Dhabi Health Services (SEHA) announced the launch of the Best of ASCO 2026 UAE conference, a specialist oncology event taking place on June 27–28, 2026 at Tawam Hospital in Al Ain. The Best of ASCO 2026 UAE brings together leading cancer specialists from across the United Arab Emirates to review recent scientific developments and assess their relevance to clinical practice.
Programme overview and ASCO abstracts
The two-day programme includes eight scientific sessions, 47 ASCO-licensed abstracts, and 15 partner-sponsored sessions designed to highlight practice-changing evidence. Additionally, the curriculum covers major tumour types and cross-cutting topics, ranging from breast and gastrointestinal cancers to lung cancer, genitourinary malignancies, hematologic disorders, melanoma and immunotherapy, sarcomas and central nervous system tumours.
Organisers said the event will emphasise translation of global evidence into local practice, and the inclusion of ASCO abstracts aims to ensure attendees see current, peer-reviewed findings alongside expert interpretation. This approach positions the meeting as a focused oncology conference for clinicians seeking concise, applicable updates.
Participants, leadership and multidisciplinary focus
The conference offers a concentrated platform for medical oncologists, hematologists, radiation oncologists, surgeons, oncology pharmacists, nursing staff and allied health professionals, as well as healthcare leaders involved in cancer services. Dr. Khaled Saeed Bal’araj, head of Oncology at Tawam Hospital and chair of the organising committee, will preside over sessions that foster interdisciplinary dialogue and case-based learning.
Through expert-led panels and moderated discussions, the organisers aim to promote multidisciplinary teamwork and shared decision-making in cancer management. Consequently, the meeting will address not only disease-specific advances but also models of care delivery and supportive treatment services that affect patient outcomes.
Clinical relevance and local practice implications
The meeting seeks to convert selected international oncology findings into practical recommendations tailored to the UAE healthcare environment. Therefore, sessions will explore how novel data should influence diagnostic pathways, treatment selection and follow-up strategies in local settings with varying resource and population considerations.
Furthermore, the event will examine quality-of-care measures and integrated service models that can improve continuity and safety of cancer care. By focusing on implementation, the conference aims to help clinicians adapt evidence to operational realities in the region.
Educational goals and professional development
Best of ASCO 2026 UAE is framed as an educational forum where specialists can exchange clinical experience and update competencies across tumour streams. The programme’s mix of abstract presentations and partner-sponsored sessions is intended to support continuing professional development and multidisciplinary learning.
Attendees should expect succinct reviews of high-priority studies, practical case discussions and opportunities for networking that may inform local guideline development and institutional protocols. In that respect, the conference acts as both an information distillation platform and a catalyst for collaborative practice improvement.
Context: the role of Best of ASCO events
Best of ASCO events typically distil highlights from the American Society of Clinical Oncology’s annual scientific meeting, according to organisers, offering regional audiences curated insights without the need to attend the global meeting. As an oncology conference format, it aims to bridge the gap between global evidence and local implementation.
For clinicians in the UAE, the meeting provides targeted exposure to ASCO abstracts and expert interpretation, which can shorten the time between publication of new evidence and clinical application. This is particularly relevant in fast-moving areas such as immunotherapy and targeted treatments.
Partner involvement and sponsored sessions
Fifteen sessions are listed as sponsored by scientific partners, allowing for deeper dives into therapeutic areas and emerging technologies. Organisers emphasise that sponsored sessions will be clearly identified and designed to complement the independent scientific programme.
What to watch next
Following the two-day meeting, attendees and institutions will likely monitor how selected findings are incorporated into local practice and whether follow-up educational activities are scheduled to support implementation. Organisers indicated that subsequent workshops, guideline reviews or institution-level audits could follow as clinicians adapt new evidence.
Readers should watch for post-conference summaries, updated institutional protocols and any announced continuing education events that build on topics covered at Best of ASCO 2026 UAE. These next steps will determine how effectively the meeting’s learning objectives translate into improved cancer care in the UAE.